Stock listing
KAPA Stock Price, News, Filings & Events — Kairos Pharma, Ltd.
Selected listing: KAPA · AMEX · USD · US
This page tracks Kairos Pharma, Ltd.'s KAPA:AMEX listing on AMEX in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following KAPA:AMEX. KAPA:AMEX is the stock-level entry point for investors researching Kairos Pharma, Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Kairos Pharma, Ltd. (Ticker: KAPA) is a public company based in America with a market capitalization of approximately $6.1 million. The company is focused on developing innovative pharmaceutical solutions. Investors can find detailed information about its operations and market presence on its public company page.

- Ticker
- KAPA:AMEX
- Asset type
- Stock
- Market cap
- $6.0M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- AMEX
- Currency
- USD
Kairos Pharma, Ltd. KAPA:AMEX stock context
This page tracks Kairos Pharma, Ltd.'s KAPA:AMEX listing on AMEX in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following KAPA:AMEX. KAPA:AMEX is the stock-level entry point for investors researching Kairos Pharma, Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Kairos Pharma, Ltd. (Ticker: KAPA) is a public company based in America with a market capitalization of approximately $6.1 million. The company is focused on developing innovative pharmaceutical solutions. Investors can find detailed information about its operations and market presence on its public company page.
Latest news from Kairos Pharma, Ltd.
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Kairos Pharma Announces 1-for-7 Reverse Stock Split
August 21, 2026
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10...
July 15, 2026
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
June 4, 2026
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
May 14, 2026
Research Kairos Pharma, Ltd.
Kairos Pharma, Ltd. investor report
Review AI stock analysis and investor report context for KAPA:AMEX.
Kairos Pharma, Ltd. company profile
View the public company page for Kairos Pharma, Ltd. on 6ix.
Kairos Pharma, Ltd. news
Read company news and market updates connected to Kairos Pharma, Ltd..
Kairos Pharma, Ltd. investor events
Find investor webinars, events, and replay context for Kairos Pharma, Ltd..